Multiple dose netivudine, a potent anti-varicella zoster virus agent, in healthy elderly volunteers and patients with shingles. 1996

R W Peck, and P Crome, and M J Wood, and M W McKendrick, and B Bannister, and B K Mandal, and R J Crooks
Wellcome Research Laboratories, Beckenham, Kent, UK.

Netivudine is a nucleoside analogue with potent anti-varicella zoster virus activity. We now report two open studies of the pharmacokinetics and tolerability of netivudine in doses of 50, 100 and 200 mg twice daily. In one study, healthy volunteers received an initial, single dose followed, a week later, by repeat dosing for 9 1/2 days; in the other, patients with shingles were treated for 8 days and data were also recorded for rash resolution and pain duration and intensity. Netivudine was well tolerated in both studies. Plasma concentrations were similar in patients and healthy volunteers and increased in proportion to dose. Steady state concentrations were 15-25% lower than expected from single dose data, probably because of slightly decreased netivudine absorption after food. Elimination half-life was l4-20 h. Plasma concentrations of 5-propynyluracil (5-PU), the main metabolite of netivudine, did not increase in proportion to the netivudine dose and tended to be higher in patients than volunteers. 5-PU concentrations remained elevated for up to 72 h after the last netivudine dose, suggesting continued but slow release from unabsorbed netivudine in the gut lumen. New lesion formation ceased and vesicles crusted most quickly in the 200 mg group; zoster-associated pain intensity, was reduced in a dose-related manner.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010349 Patient Compliance Voluntary cooperation of the patient in following a prescribed regimen. Client Adherence,Client Compliance,Non-Adherent Patient,Patient Adherence,Patient Cooperation,Patient Noncompliance,Patient Non-Adherence,Patient Non-Compliance,Patient Nonadherence,Therapeutic Compliance,Treatment Compliance,Adherence, Client,Adherence, Patient,Client Compliances,Compliance, Client,Compliance, Patient,Compliance, Therapeutic,Compliance, Treatment,Cooperation, Patient,Non Adherent Patient,Non-Adherence, Patient,Non-Adherent Patients,Non-Compliance, Patient,Nonadherence, Patient,Noncompliance, Patient,Patient Non Adherence,Patient Non Compliance,Patient, Non-Adherent,Therapeutic Compliances,Treatment Compliances
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006562 Herpes Zoster An acute infectious, usually self-limited, disease believed to represent activation of latent varicella-zoster virus (HERPESVIRUS 3, HUMAN) in those who have been rendered partially immune after a previous attack of CHICKENPOX. It involves the SENSORY GANGLIA and their areas of innervation and is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area. (From Dorland, 27th ed) Shingles,Zona,Zoster
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral

Related Publications

R W Peck, and P Crome, and M J Wood, and M W McKendrick, and B Bannister, and B K Mandal, and R J Crooks
May 1996, The Journal of antimicrobial chemotherapy,
R W Peck, and P Crome, and M J Wood, and M W McKendrick, and B Bannister, and B K Mandal, and R J Crooks
January 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987),
R W Peck, and P Crome, and M J Wood, and M W McKendrick, and B Bannister, and B K Mandal, and R J Crooks
December 2003, Professional nurse (London, England),
R W Peck, and P Crome, and M J Wood, and M W McKendrick, and B Bannister, and B K Mandal, and R J Crooks
November 1983, Lancet (London, England),
R W Peck, and P Crome, and M J Wood, and M W McKendrick, and B Bannister, and B K Mandal, and R J Crooks
August 2006, Expert review of vaccines,
R W Peck, and P Crome, and M J Wood, and M W McKendrick, and B Bannister, and B K Mandal, and R J Crooks
January 2010, Antiviral chemistry & chemotherapy,
R W Peck, and P Crome, and M J Wood, and M W McKendrick, and B Bannister, and B K Mandal, and R J Crooks
January 2009, Annals of clinical and laboratory science,
R W Peck, and P Crome, and M J Wood, and M W McKendrick, and B Bannister, and B K Mandal, and R J Crooks
June 2005, Medizinische Monatsschrift fur Pharmazeuten,
R W Peck, and P Crome, and M J Wood, and M W McKendrick, and B Bannister, and B K Mandal, and R J Crooks
January 2006, MMW Fortschritte der Medizin,
R W Peck, and P Crome, and M J Wood, and M W McKendrick, and B Bannister, and B K Mandal, and R J Crooks
April 2016, Revue medicale suisse,
Copied contents to your clipboard!